Docoh
Loading...

CNTG Centogene

CENTOGENE engages in diagnosis and research around rare diseases transforming real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies. Its goal is to bring rationality to treatment decisions and to accelerate the development of new orphan drugs by using its extensive rare disease knowledge, including epidemiological and clinical data, as well as innovative biomarkers. CENTOGENE has developed a global proprietary rare disease platform based on its real-world data repository with over 3.6 billion weighted data points from approximately 595,000 patients representing over 120 different countries as of September 30, 2020. The Company's platform includes epidemiologic, phenotypic, and genetic data that reflects a global population, and also a biobank of these patients' blood samples. CENTOGENE believes this represents the only platform that comprehensively analyzes multi-level data to improve the understanding of rare hereditary diseases, which can aid in the identification of patients and improve its pharmaceutical partners' ability to bring orphan drugs to the market. As of September 30, 2020, the Company collaborated with over 40 pharmaceutical partners covering over 45 different rare diseases.

Company profile

CNTG stock data

(
)

Calendar

15 Apr 21
14 Jun 21
31 Dec 21
Quarter (USD)
Dec 20 Dec 19
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from Centogene earnings reports.

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

25.3% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 1 37 -97.3%
Opened positions 1 10 -90.0%
Closed positions 37 3 +1133.3%
Increased positions 0 19 EXIT
Reduced positions 0 6 EXIT
13F shares
Current Prev Q Change
Total value 68.15M 29.68M +129.6%
Total shares 5.6M 3.14M +78.5%
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners
Shares Value Change
DPE Deutsche Private Equity Gesellschaft mbH 5.6M $68.15M NEW
Largest transactions
Shares Bought/sold Change
DPE Deutsche Private Equity Gesellschaft mbH 5.6M +5.6M NEW
BLK Blackrock 0 -422.13K EXIT
Alyeska Investment 0 -411.08K EXIT
Platinum Investment Management 0 -374.7K EXIT
GS Goldman Sachs 0 -353.84K EXIT
FHI Federated Hermes 0 -324.94K EXIT
Royce & Associates 0 -200K EXIT
Sabby Management 0 -182.28K EXIT
Granahan Investment Management 0 -120.82K EXIT
NTRS Northern Trust 0 -108K EXIT

Financial report summary

?
Competition
InvitaeFulgent Genetics
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg

Proxies

No filings